Clovis’ Rociletinib May Get Back On Track With FDA Panel Review in April
This article was originally published in The Pink Sheet Daily
Executive Summary
New filing package for third-generation EGFR inhibitor will be reviewed by FDA’s Oncology Drugs Advisory Committee on April 12.